share_log

Evercore ISI Group Maintains Outperform on Avidity Biosciences, Raises Price Target to $54

Evercore ISI Group Maintains Outperform on Avidity Biosciences, Raises Price Target to $54

Evercore ISI集团维持对avidity biosciences的跑赢大盘评级,将价格目标上调至54美元。
Benzinga ·  08/12 10:04  · 评级/大行评级

Evercore ISI Group analyst Josh Schimmer maintains Avidity Biosciences (NASDAQ:RNA) with a Outperform and raises the price target from $45 to $54.

Evercore ISI集团分析师Josh Schimmer维持对Avidity Biosciences(纳斯达克:RNA)的跑赢大市评级,并将目标股价从45美元升至54美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发